Table 1.
Patient, tumor and treatment characteristics
Characteristic | n | Percent | |
Age (yr), median | 54 (range, 32-75) | ||
Sex | Male | 44 | 86.3 |
Female | 7 | 13.7 | |
Viral type | B | 44 | 86.3 |
C | 4 | 7.8 | |
NBNC | 3 | 5.9 | |
Child-Pugh class | A | 49 | 96.1 |
B | 2 | 3.9 | |
Modified UICC stage | II | 4 | 7.8 |
III | 32 | 62.7 | |
IV | 15 | 29.5 | |
BCLC stage | A | 14 | 27.5 |
B | 12 | 23.5 | |
C | 25 | 49.0 | |
PVT | No | 31 | 60.8 |
Yes | 20 | 39.2 | |
Multiplicity | No | 25 | 49.0 |
Yes | 26 | 51.0 | |
Tumor size in cm, median | 8.5 (range, 1.0-19.6) | ||
AFP (IU/mL), median | 141.9 (range, 1.53-83000) | ||
PIVKA-II (mAU/mL), median | 600 (range, 12-2000) | ||
Treatment-naïve | Yes | 29 | 56.9 |
No | 22 | 43.1 | |
Total dose of RT (Gy), median | 50.4 (range, 45-64.8) |
NBNC: Non-B non-C; UICC: International Union Against Cancer; BCLC: Barcelona Clinic Liver Cancer; PVT: Portal vein thrombosis; AFP: α-fetoprotein; PIVKA-II: Prothrombin induced by vitamin K absence-II; RT: Radiotherapy.